Diagnostic Center | December 17, 2024
Merck to discontinue KeyVibe and Keyform clinical trials
Merck has also decided to end the favezelimab clinical development program
Merck has also decided to end the favezelimab clinical development program
Venus Remedies secures marketing authorization in Philippines
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Subscribe To Our Newsletter & Stay Updated
